跳至主要内容
临床试验/NCT05142410
NCT05142410已完成不适用

A Retrospective Study Using Mass Spectrometry to Characterize Post-translational Modifications to Circulating Histones in Pregnant Women Developing Pre-eclampsia

Centre Hospitalier Universitaire de Nīmes1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2019年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
28
试验地点
1
主要终点
Presence of methylation in histone H2A in pregnant women developing pre-eclampsia

研究概览

简要总结

This is a descriptive pilot study on a ready-constituted biobank (outside the Jardé Law). It is an ancillary study to the "GrossPath" cohort (RCB ID number: 2014-A01120-47).

Pregnancy generates an increased risk of thrombosis, and placenta-mediated diseases constitute a risk factor for cardiovascular pathologies responsible for significant maternal-fetal morbidity and mortality. Understanding and exploring the cellular and molecular mechanisms of dysfunctions of the vascular-placental interface could provide arguments to understand the systemic vascular risk, characterize it and finally detect it on the basis of new markers, thus opening the way for targeted preventive management to reinforce the general principles of precision medicine.

Netosis is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Netosis occurs in pregnancy and is increased in vascular-placental complications. It can be studied by measuring circulating histones, particularly the citrullinated histone H3. Levels of this modified histone H3, as well as those of two other modifications, have recently been shown to increase during pregnancy. These levels have also been shown to be even greater in pregnancy complications.

The aim of this study is to complete this mapping in order to obtain a precise signature for all post-translational histone modifications in normal pregnancies and pregnancies complicated by pre-eclampsia from the "GrossPath" cohort in order to propose new circulating biomarkers for placental vascular pathologies.

The post-translational histone modification profiles (mapping) of pregnant women with normal pregnancies will be compared with those developing pre-eclampsia.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Not applicable as this study is on samples from a biobank. The inclusion criteria for the "GrossPath" cohort were:
  • pregnant women followed at Nîmes University hospital for normal pregnancy or pregnancy with placental vascular pathology (pre-eclampsia and/or intra-uterine growth retardation).
  • The patient must have given her free and informed consent and signed the consent form.
  • The patient must be a member or beneficiary of a health insurance plan
  • Only women are included
  • Patients are at least 18 years old

排除标准

  • Not applicable as this is a study on samples from a biobank. The non-inclusion criteria of the "GrossPath" cohort were :
  • twin pregnancies.

结局指标

主要结局

Presence of methylation in histone H2A in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.

Presence of methylation in histone H3 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.

Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.

Presence of phosphorylation in histone H2B in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.

Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.

Presence of methylation in histone H3 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.

Presence of phosphorylation in histone H2A in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.

Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.

Presence of methylation in histone H2B in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.

Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.

Presence of methylation in histone H4 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.

Presence of acetylation in histone H2A in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.

Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.

Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.

Presence of ubiquitination in histone H2A in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.

Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.

Presence of ubiquitination in histone H4 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.

Presence of citrullination in histone H3 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.

Presence of methylation in histone H2A in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.

Presence of methylation in histone H2B in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.

Presence of methylation in histone H4 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.

Presence of acetylation in histone H4 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.

Presence of phosphorylation in histone H3 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.

Presence of ubiquitination in histone H2B in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.

Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.

Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.

Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.

Presence of acetylation in histone H2B in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.

Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.

Presence of acetylation in histone H3 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.

Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.

Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.

Presence of ubiquitination in histone H3 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.

Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.

Presence of citrullination in histone H2B in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.

Presence of citrullination in histone H4 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.

Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.

Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.

Presence of phosphorylation in histone H4 in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.

Presence of citrullination in histone H2A in pregnant women with normal pregnancies

时间窗: At pregnancy term (max 41 weeks gestation)

Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.

次要结局

  • Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of acetylation in histone H2B in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of methylation in histone H2A in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of methylation in histone H3 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of methylation in histone H4 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of acetylation in histone H2A in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of ubiquitination in histone H4 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H4 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Presence of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(After 34 weeks of pregnancy)
  • Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of methylation in histone H2B in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of acetylation in histone H3 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of ubiquitination in histone H2A in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H3 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Presence of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of phosphorylation in histone H3 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of phosphorylation in histone H2A in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of acetylation in histone H4 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of phosphorylation in histone H2B in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of phosphorylation in histone H4 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of ubiquitination in histone H3 in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H2A in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Presence of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 of pregnancy)
  • Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of ubiquitination in histone H2B in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H2B in pregnant women with normal pregnancies(At pregnancy term (max 41 weeks gestation))
  • Presence of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 of pregnancy)
  • Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia(At pregnancy term (max 41 weeks gestation))
  • Presence of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.(34 to 41 weeks of pregnancy)
  • Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.(34 to 41 weeks of pregnancy)
  • Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.(Before 34 weeks of pregnancy)
  • Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy(34 to 41 weeks of pregnancy)
  • Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy(Before 34 weeks of pregnancy)
  • Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.(Before 34 weeks of pregnancy)

研究者

发起方
Centre Hospitalier Universitaire de Nīmes
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验